OS Therapies (OSTX) Cash & Equivalents (2023 - 2026)

OS Therapies (OSTX) has 4 years of Cash & Equivalents data on file, last reported at $917552.0 in Q1 2026.

• Quarterly Cash & Equivalents fell 69.12% year-over-year to $917552.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $917552.0 (down 69.12% YoY) and the FY2025 annual result came in at $269830.0, down 95.12% from the prior year.
• Cash & Equivalents rose to $917552.0 in Q1 2026, from $269830.0 in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $5.5 million in Q4 2024 to a low of $16059.0 in Q3 2023.
• A 4-year average of $1.3 million and a median of $355214.0 in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2024 — Cash & Equivalents surged 14095.08% — and 2025, when it tumbled 95.12%.
• Tracing OSTX's Cash & Equivalents over 4 years: stood at $38982.0 in 2023, then surged by 14095.08% to $5.5 million in 2024, then plunged by 95.12% to $269830.0 in 2025, then surged by 240.05% to $917552.0 in 2026.
• The last three Cash & Equivalents figures came in at $917552.0 (Q1 2026), $269830.0 (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.